Clinical Trials

Novartis announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. Initial data show there was no...

As the various COVID-19 vaccines move closer to the finish line, their developers have been raising money from investors or through advance government purchases to ramp up manufacturing. Now, a Chinese company has done the same for its candidate. Sinovac...

Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety...

Roche announced a partnership with Moderna Inc. to utilise the Elecsys® Anti-SARS-CoV-2 S antibody test in Moderna’s mRNA-1273 vaccine research trials. This will facilitate the quantitative measurement of SARS-CoV-2 antibodies and help to establish a correlation between vaccine-induced protection...

INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800, a DNA vaccine against the novel coronavirus SARS-CoV-2. INOVIO’s President & CEO, Dr. J. Joseph Kim, said, “Our partnership with Kaneka Eurogentec,...

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that the final patient has been enrolled in its multinational phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from...

Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As per a statement from the vaccine maker, the event was reported in a timely manner...